The gross proceeds to
The securities described above are being offered and sold in this registered direct offering pursuant to a shelf registration statement, including a prospectus, on Form S-3 that was filed by
This press release shall not constitute an offer to sell or a solicitation of an offer to buy Nabriva Therapeutics’ securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for
CONTACTS:
For Investors
IR@Nabriva.com
For Media
mikebeyer@sambrown.com
312-961-2502
Source: Nabriva Therapeutics US, Inc